ARBITER 2 Trial

Revision as of 14:31, 21 October 2013 by Rim Halaby (talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

High Density Lipoprotein Microchapters

Home

Patient information

Overview

Historical Perspective

Classification

Physiology

Pathophysiology

Causes

Low HDL
High HDL

Epidemiology and Demographics

Screening

Natural History, Complications and Prognosis

Diagnosis

HDL Laboratory Test

Treatment

Medical Therapy

Prevention

Future or Investigational Therapies

Clinical Trials

Landmark Trials

List of All Trials

Case Studies

Case #1

ARBITER 2 Trial On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of ARBITER 2 Trial

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on ARBITER 2 Trial

CDC on ARBITER 2 Trial

ARBITER 2 Trial in the news

Blogs on ARBITER 2 Trial

Directions to Hospitals Treating High density lipoprotein

Risk calculators and risk factors for ARBITER 2 Trial

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Click here to download slides for ARBITER-2 Trial.

Objective

To assess if treatment with extended release niacin when added to statin monotherapy slows progression of atherosclerosis among individuals with known coronary artery disease (CAD) and moderately low HDL-C.

Methods

ARBITER (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol) 2 was a double blinded randomized placebo controlled study of once daily extended release niacin (1000 mg). 167 patients with known CAD and moderately low HDL-C were enrolled in this study and were assessed for the primary end-point carotid intima-media thickness (CIMT) at the end of one year.

Results

At the end of 12 months mean CIMT significantly increased in the placebo group but not in the niacin group. Niacin significantly reduced the rate of IMT progression in patients without insulin resistance. Patients treated with niacin had a significant increase in HDL levels from a mean of 39 mg/dL to 47 mg/dL. Clinical cardiovascular events occurred in 3 patients on niacin and 7 patients treated with placebo.

Conclusion

The addition of extended-release niacin to statin therapy slowed the progression of atherosclerosis among individuals with known coronary heart disease and moderately low HDL-C.[1]

References

  1. Taylor AJ, Sullenberger LE, Lee HJ, Lee JK, Grace KA (2004). "Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins". Circulation. 110 (23): 3512–7. doi:10.1161/01.CIR.0000148955.19792.8D. PMID 15537681. Unknown parameter |month= ignored (help)